In May 2023, China’s National Medical Products Administration (NMPA) approved the first domestically developed generic version of olaparib tablets. Developed by Qilu Pharmaceutical, this olaparib product was officially approved on May 12 and subsequently launched under the brand name Qipani®.…
In recent years, immune checkpoint inhibitors have revolutionized the field of anti-tumor treatment, among which PD-1 (programmed death protein 1) monoclonal antibodies have become a core therapeutic option for multiple advanced tumors due to their unique mechanism of action and…
In the treatment of leukemia, not all patients respond equally to standard therapies. Drug resistance and genetic mutations can significantly reduce the effectiveness of commonly used treatments, creating an urgent need for more advanced targeted options. At the same time,…
Adebrelimab approval in China marks a significant milestone in the country’s oncology landscape. In 2023, China’s National Medical Products Administration (NMPA) approved adebrelimab injection (Airuili®) for use in combination with standard chemotherapy as a first-line treatment for extensive-stage small cell…
Multiple myeloma is a chronic and often relapsing hematologic malignancy that requires long-term, repeated treatment. Over the past decade, therapeutic advances—particularly the introduction of monoclonal antibodies—have significantly improved patient outcomes. ✨ Among these, Daratumumab has become a cornerstone therapy across…
Biologic therapies have fundamentally changed how chronic inflammatory diseases are treated, shifting the focus from broad immunosuppression to targeted immune modulation. From this evolving therapeutic landscape, DengYue Medicine has closely followed the emergence of next-generation biologics that redefine standards of…
What is Taltz ixekizumab used for? This is a common question among patients and healthcare professionals seeking clearer information about modern biologic therapies for immune-mediated inflammatory diseases. As treatment strategies continue to evolve toward targeted and precision-based approaches, understanding how…
In global oncology practice, cancer anorexia–cachexia syndrome (CACS) is a common and clinically significant complication, characterized by appetite loss, involuntary weight loss, and skeletal muscle wasting. This condition not only reduces quality of life but also impairs treatment tolerance and…
Lung cancer has long been one of the leading causes of cancer incidence and mortality worldwide. With rapid advances in molecular biology, immunology, and drug development, lung cancer treatment is undergoing a profound transformation. In recent years, a wave of…
Prostate cancer remains one of the most commonly diagnosed malignancies among men worldwide, and despite significant advances in diagnosis and treatment, disease progression and therapeutic resistance continue to pose major clinical challenges. Ariane (rezvilutamide) as a novel androgen receptor inhibitor,…
